global dementia legacy event: elisabetta vaudano dvm phd
DESCRIPTION
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia. Elisabetta Vaudano DVM PhD, Coordinator Scientific Pillar, Principal Scientific Manager, Innovative Medicines InitiativeTRANSCRIPT
![Page 1: Global Dementia Legacy Event: Elisabetta Vaudano DVM PhD](https://reader034.vdocuments.net/reader034/viewer/2022052522/554b020bb4c90559058b5405/html5/thumbnails/1.jpg)
- Innovative Medicines Initiative -
Elisabetta Vaudano
![Page 2: Global Dementia Legacy Event: Elisabetta Vaudano DVM PhD](https://reader034.vdocuments.net/reader034/viewer/2022052522/554b020bb4c90559058b5405/html5/thumbnails/2.jpg)
Open collaboration in public-private consortia
(data sharing, dissemination of results)
“Non-competitive” collaborative research for EFPIA pharma companies
Competitive calls to select partners of
EFPIA companies
Key Concepts of IMI
![Page 3: Global Dementia Legacy Event: Elisabetta Vaudano DVM PhD](https://reader034.vdocuments.net/reader034/viewer/2022052522/554b020bb4c90559058b5405/html5/thumbnails/3.jpg)
REGULATORS ON BOARD OF
12PROJECTS
50% of projects have REGULATORY AUTHORITIES
representatives in Scientific Advisory Boards
61% of projects reported some form of
PATIENT INVOLVEMENT
![Page 4: Global Dementia Legacy Event: Elisabetta Vaudano DVM PhD](https://reader034.vdocuments.net/reader034/viewer/2022052522/554b020bb4c90559058b5405/html5/thumbnails/4.jpg)
Key collaborative activity areas: Diabetes, CNS disorders, Tuberculosis, Patient Reported Outcomes,
Cancer, Preclinical Safety and Education & Training.
IMI signed horizontal agreements with:Critical Path, Juvenile Diabetes Research Foundation as well as
with Clinical Data Interchange Standards Consortium.
Collaboration
![Page 5: Global Dementia Legacy Event: Elisabetta Vaudano DVM PhD](https://reader034.vdocuments.net/reader034/viewer/2022052522/554b020bb4c90559058b5405/html5/thumbnails/5.jpg)
€ 1 945 135 308
€ 759,185,796Infectious diseases
€ 214,136,227Drug discovery
€ 182,980,698Brain disorders
€ 116,880,300Metabolic disorders
€ 116,287,312Drug safety
€ 78,225,417Stem cells
€ 72,710786Cancer
IMI funding
Corporate contribution
€ 70,310,746Data management
€ 69,739,527Inflammatory disorders
€ 55,930,958Biologicals
€ 49,310,000Geriatrics
€ 37,966,496Lung diseases
€ 37,378,289Education andtraining
€ 30,601,855Sustainablechemistry
€ 20,426,255Drug delivery
€ 18,118,249Drug kinetics
€ 14,910,397Relative effectiveness
NATURE MEDICINE | NEWS
PartnersAiCuris Johnson&JohnsonAnimal Health MedimmuneDivision of Sanofi Merck Astellas Merck SharpAstraZeneca & Dohme CorpBasilea MerialBoehringer Ingelheim NovartisCubist PfizerGSK RempexJanssen Sanofi
AstraZeneca NovartisBayer PfizerJanssen Sanofi Lundbeck UCBMerck
Abbott Janssen AbbVie LundbeckAC IMMUNE MerckAmgen NovartisAstellas NOVO NORDISKAstraZeneca Orion CorporationBIOGEN IDEC PfizerBoehringer Ingelheim RocheEisai SanofiEli Lilly SERVIERESTEVE UCBGrunenthal ViforGSK
First phase of Europe’s IMI effort: budget breakdown
![Page 6: Global Dementia Legacy Event: Elisabetta Vaudano DVM PhD](https://reader034.vdocuments.net/reader034/viewer/2022052522/554b020bb4c90559058b5405/html5/thumbnails/6.jpg)
IMI invests €167 million in 4 projects aiming at:
Developing models to predict the efficacy of drug candidates in patients
Connecting data on 40 millions of individuals to decipher links between genetic background, biological abnormalities, brain imaging changes, mental symptoms and disease progression
Identifying subgroups of the disease allowing to tailor therapies according to the different causal factors involved
Implementing innovative trial designs
How IMI addresses Alzheimer’s disease
![Page 7: Global Dementia Legacy Event: Elisabetta Vaudano DVM PhD](https://reader034.vdocuments.net/reader034/viewer/2022052522/554b020bb4c90559058b5405/html5/thumbnails/7.jpg)
January 2014
![Page 8: Global Dementia Legacy Event: Elisabetta Vaudano DVM PhD](https://reader034.vdocuments.net/reader034/viewer/2022052522/554b020bb4c90559058b5405/html5/thumbnails/8.jpg)
The Vision for IMI2 – The right prevention and treatment for the right patient at the right time
Biologically heterogeneous
patient population
Graphic adapted from C. Carini, C. Fratazzi, Eur. Pharm. Rev. 2008, 2, 39-45
effective
noteffective
Adverseevents
Trial and Error
effective
noteffective
adverseevents
Dx Test
A
B
Ce.g. biomarker
Information based treatment decisions
vs
The Next Phase: IMI2
![Page 9: Global Dementia Legacy Event: Elisabetta Vaudano DVM PhD](https://reader034.vdocuments.net/reader034/viewer/2022052522/554b020bb4c90559058b5405/html5/thumbnails/9.jpg)
IMI2 Key Facts and Strategic Research Agenda
Bigger budget: 3,45 Billion Euro, equally shared by EU and industry
Partnership Not limited to EFPIA members
Dementia and Neurodegeneration have been identified as key research priorities
![Page 10: Global Dementia Legacy Event: Elisabetta Vaudano DVM PhD](https://reader034.vdocuments.net/reader034/viewer/2022052522/554b020bb4c90559058b5405/html5/thumbnails/10.jpg)
Thank youwww.imi.europa.eu
@IMI_JU